HIMS vs TDOC Stock Comparison: AI Score, Valuation, Performance and Upside
Hims & Hers and Teladoc both operate in digital health, but Hims & Hers pursues a direct-to-consumer subscription model marketed directly to individual consumers across wellness categories, while Teladoc operates a more enterprise-oriented model distributed through employer and health plan relationships.
Hims & Hers offers exposure to a fast-growing, direct-to-consumer digital health brand with weight management momentum, while Teladoc offers exposure to a more established, enterprise-distributed telehealth platform working through a growth reset. Consider whether you prefer Hims & Hers's consumer brand growth story or Teladoc's enterprise distribution scale.
TDOC holds the edge across 3 of 5 key metrics in this comparison. TDOC has delivered stronger 1-year price return (-2.63% vs -37.18%), though HIMS has the better forward P/E setup (29.03x vs -8.23x for TDOC). On fundamentals, HIMS is growing revenue faster (38.20%), while TDOC maintains the higher operating margin (-5.68%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for TDOC (+18.68%) than for HIMS (+7.36%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a fast-growing, direct-to-consumer digital health subscription brand
- Believe continued weight management and GLP-1 related category momentum will drive substantial growth
- Are comfortable with marketing spend requirements pressuring near-term margins
- Value a direct customer relationship model without intermediary payer dependency
- Want exposure to a diversified virtual care provider spanning general medical, mental health, and chronic care services
- Believe scale advantages support broader service coverage and provider network depth
- Value established relationships with health plans and employers as a distribution channel
- Prefer an enterprise-distributed telehealth model over a direct-to-consumer subscription brand
| Metric | HIMS | TDOC |
|---|---|---|
| AI scorei | 43.6 | 25.2 |
| AI ranki | #848 | #2968 |
| Latest closei | $27.68 | $8.51 |
| 1M returni | -7.08% | +46.72% |
| 3M returni | -0.32% | +26.83% |
| 6M returni | +0.99% | +31.73% |
| 1Y returni | -37.18% | -2.63% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HIMS | TDOC |
|---|---|---|
| 1Y ago | $6.28K (-37.2%) started 2025-10-30 | $9.74K (-2.6%) started 2025-10-30 |
| 5Y ago | $33.71K (+237.1%) started 2021-11-01 | $561.6 (-94.4%) started 2021-11-01 |
| 10Y ago | $28.24K (+182.4%) started 2019-09-13 | $5.24K (-47.6%) started 2016-10-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | HIMS | TDOC |
|---|---|---|
| Market capi | $6.79B | $1.17B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | 29.03 | -8.23 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 2.85 | 0.56 |
| Analyst targeti | $31.23 | $7.67 |
| Target upsidei | +7.36% | +18.68% |
| Metric | HIMS | TDOC |
|---|---|---|
| Revenue growthi | 38.20% | -4.00% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +32.95% | +7.67% |
| Operating margini | -12.75% | -5.68% |
| Profit margini | -5.51% | -7.13% |
| ROIC proxyi | -32.03% | -12.98% |
| Return on equityi | -32.03% | -12.98% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | 2.42 | 2.13 |
| Debt/equityi | 477.13 | 79.09 |
| Current ratioi | 0.93 | 0.83 |
| Quick ratioi | 0.82 | 0.73 |
Over the past year, HIMS and TDOC have moved weakly in the same direction (correlation of 0.28), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HIMS | TDOC |
|---|---|---|---|
| 1Y | Growthi | -37.18% | -2.63% |
| CAGRi | -37.20% | -2.63% | |
| Volatilityi | 88.94% | 65.40% | |
| Sharpe ratioi | -0.15 | 0.22 | |
| Sortino ratioi | -0.23 | 0.33 | |
| Max drawdowni | 68.06% | 48.86% | |
| Current drawdowni | 39.11% | 12.45% | |
| Avg drawdowni | 36.00% | 26.42% | |
| Ulcer Indexi | 38.62% | 29.45% | |
| Max daily dropi | 16.03% | 28.32% | |
| Max wkly dropi | 32.71% | 28.31% | |
| 5Y | Growthi | +237.15% | -94.38% |
| CAGRi | +27.55% | -43.82% | |
| Volatilityi | 84.26% | 66.82% | |
| Sharpe ratioi | 0.65 | -0.59 | |
| Sortino ratioi | 1.02 | -0.82 | |
| Max drawdowni | 78.88% | 97.10% | |
| Current drawdowni | 59.73% | 94.48% | |
| Avg drawdowni | 33.26% | 85.47% | |
| Ulcer Indexi | 38.30% | 86.85% | |
| Max daily dropi | 34.63% | 40.15% | |
| Max wkly dropi | 39.06% | 43.25% | |
| 10Y | Growthi | +182.45% | -47.63% |
| CAGRi | +15.68% | -6.27% | |
| Volatilityi | 77.37% | 61.42% | |
| Sharpe ratioi | 0.51 | 0.13 | |
| Sortino ratioi | 0.79 | 0.19 | |
| Max drawdowni | 87.29% | 98.48% | |
| Current drawdowni | 59.73% | 97.11% | |
| Avg drawdowni | 43.90% | 54.70% | |
| Ulcer Indexi | 52.22% | 67.60% | |
| Max daily dropi | 34.63% | 40.15% | |
| Max wkly dropi | 39.06% | 43.25% |
| Category | HIMS | TDOC |
|---|---|---|
| Company | Hims & Hers Health, Inc. | Teladoc Health, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Health Information Services |
| Core business | A direct-to-consumer telehealth and wellness company offering subscription-based access to medical consultations and treatments across categories including sexual health, dermatology, mental health, and weight management. | A virtual care company providing telehealth services including general medical consultations, mental health support, and chronic condition management through a technology platform serving individual, employer, and health plan customers. |
| Investor focus | Subscriber growth and revenue per subscriber trends, weight management category momentum including GLP-1 related treatments, and marketing spend efficiency. | Mental health and chronic care segment growth, membership and utilization trends, and progress toward sustained profitability following the post-pandemic demand normalization. |
- Direct-to-consumer subscription model provides recurring revenue and direct customer relationships without intermediary payers
- Strong brand marketing and consumer-facing positioning have driven rapid subscriber growth across multiple treatment categories
- Expansion into weight management and GLP-1 related offerings has provided a substantial incremental growth driver
- Diversified service offering spans general medical, mental health, and chronic condition management virtual care
- Established relationships with health plans and employers provide a distribution channel for telehealth services
- Scale as one of the largest telehealth providers supports broader service coverage and provider network depth
- Direct-to-consumer marketing spend requirements can pressure near-term margins as the company pursues subscriber growth
- Weight management category growth carries regulatory and competitive dynamics tied to GLP-1 drug access and pricing
- Business model relies on continued brand marketing effectiveness to maintain customer acquisition economics
- Growth rates have moderated substantially from pandemic-era peaks, requiring new demand drivers to reaccelerate
- Path to consistent profitability has required ongoing cost discipline and business model adjustments
- Competitive telehealth landscape includes both dedicated virtual care companies and traditional healthcare providers building their own offerings
Compare more than two at a time
This page is a fixed writeup on HIMS and TDOC. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside HIMS and TDOC, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.